The regulatory roles and therapeutic strategies of the solute carrier transporters in cancer metabolism

npj Precision Oncology 2026 Open access

Read full text
Authors: Xiao Ming Zhang, Jiao Feng, Xufan Cai, XU Weilang, Tao Ding, Min He, Yonghui Dong, Xiaoling Xu, Zaiyuan Ye
DOI: 10.1038/s41698-025-01198-9
Cited by: 5
References: 197

Abstract

The Solute Carrier (SLC) family regulates cancer metabolism, supporting proliferation and immune evasion. Key members, such as GLUT1, LAT1, ASCT2, xCT and MCT4, drive metabolic reprogramming and are therapeutic targets. Selective inhibitors like BAY-876 show preclinical efficacy. Combining SLC inhibition with standard therapies may overcome resistance, while personalized strategies and advances in biomarkers and drug delivery are critical for clinical translation.

Fields of Study & Subjects

Cancer Hypoxia and Metabolism Cancer Cells and Metastasis Glycosylation and Glycoproteins Research

Publication details

Journal / source
npj Precision Oncology
Publisher
Springer Science and Business Media LLC
Volume
10
Issue
1
Pages
23–23
Publication date
5 January 2026
Language
EN